Pharming Group Future Growth

Future criteria checks 4/6

Pharming Group is forecast to grow earnings and revenue by 53% and 12.3% per annum respectively while EPS is expected to grow by 54.5% per annum.

Key information

53.0%

Earnings growth rate

54.5%

EPS growth rate

Biotechs earnings growth	23.7%
Revenue growth rate	12.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	01 May 2024

Recent future growth updates

No updates

Recent updates

Pharming's rare immunodeficiency disorder drug gets FDA priority review

Sep 28

Pharming gets EMA panel nod for accelerated review of leniolisib for rare immunodeficiency disorder

Aug 01

Earnings and Revenue Growth Forecasts

NasdaqGM:PHAR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	370	44	63	56	4
12/31/2025	323	15	36	29	4
12/31/2024	281	1	27	20	4
12/31/2023	245	-11	3	-17	N/A
9/30/2023	219	-22	-4	-24	N/A
6/30/2023	206	-16	5	-15	N/A
3/31/2023	202	-2	-3	-1	N/A
12/31/2022	206	14	20	22	N/A
9/30/2022	204	30	25	33	N/A
6/30/2022	202	21	15	26	N/A
3/31/2022	202	11	17	31	N/A
12/31/2021	199	16	21	38	N/A
9/30/2021	200	22	29	43	N/A
6/30/2021	200	31	40	52	N/A
3/31/2021	202	37	59	70	N/A
12/31/2020	212	38	68	84	N/A
9/30/2020	212	44	70	85	N/A
6/30/2020	202	46	59	93	N/A
3/31/2020	202	42	53	84	N/A
1/1/2020	189	41	49	74	N/A
9/30/2019	175	38	48	70	N/A
6/30/2019	175	34	59	63	N/A
3/31/2019	158	29	54	57	N/A
12/31/2018	155	29	42	46	N/A
9/30/2018	152	-29	57	63	N/A
6/30/2018	138	-44	54	61	N/A
3/31/2018	128	-80	44	52	N/A
12/31/2017	108	-91	39	46	N/A
9/30/2017	76	-53	N/A	14	N/A
6/30/2017	47	-47	N/A	-6	N/A
3/31/2017	31	-21	N/A	-13	N/A
12/31/2016	17	-18	N/A	-11	N/A
9/30/2016	12	-16	N/A	-18	N/A
6/30/2016	12	-15	N/A	-18	N/A
3/31/2016	13	-14	N/A	-18	N/A
12/31/2015	12	-11	N/A	-19	N/A
9/30/2015	29	8	N/A	-3	N/A
6/30/2015	27	9	N/A	-1	N/A
3/31/2015	23	10	N/A	-3	N/A
12/31/2014	26	-7	N/A	-3	N/A
9/30/2014	6	-29	N/A	-19	N/A
6/30/2014	6	-35	N/A	-16	N/A
3/31/2014	11	-35	N/A	-14	N/A
12/31/2013	9	-21	N/A	-11	N/A
9/30/2013	19	-15	N/A	-8	N/A
6/30/2013	18	-19	N/A	-12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHAR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: PHAR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PHAR is expected to become profitable in the next 3 years.

Revenue vs Market: PHAR's revenue (12.3% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: PHAR's revenue (12.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHAR's Return on Equity is forecast to be high in 3 years time

Pharming Group Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Recent updates

Pharming Group N.V. announced that it expects to receive €100 million in funding

Pharming Group N.V. to Report Fiscal Year 2023 Results on Apr 04, 2024

Pharming Group N.V. to Report Q4, 2023 Results on Mar 14, 2024

Pharming Group N.V. Appoints Richard Peters as Non-Executive Director

Pharming Group N.V. Announces First Patient Enrolled in Phase Iii Clinical Trial of Leniolisib for the Treatment of Apds in Japan

Pharming Group N.V. Appoints Alexander Breidenbach as Chief Business Officer

Pharming Group N.V. Approves the Proposal to Reappoint Paul Sekhri, Chair of the Board, as Non-Executive Director for A Period of One Year Who Will Resign from the Board Upon Appointment of His Successor

Pharming Group N.V. Provides Update on EMA Regulatory Review of Leniolisib for Apds in Europe

Pharming Group N.V. Announces Positive Interim Analysis Data from Open-Label Extension Study of Leniolisib in Presentation At the 64Th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming Group N.V. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharming Group N.V. Announces Positive Results of Phase 3 Clinical Trial of Investigational Drug Leniolisib

Pharming Group N.V. Announces European Medicines Agency Validates its Marketing Authorisation Application Under Accelerated Assessment for Leniolisib

Pharming Group N.V. Submits Marketing Authorisation Application to European Medicines Agency for Leniolisib

Pharming Group N.V. Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

Pharming's rare immunodeficiency disorder drug gets FDA priority review

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Pharming gets EMA panel nod for accelerated review of leniolisib for rare immunodeficiency disorder

Pharming Group N.V. Receives Accelerated Assessment in Europe for Leniolisib for the Treatment of Rare Immunodeficiency, APDS

GIMV NV (ENXTBR:GIMB) completed the acquisition of 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM).

Pharming Receives Agreement of Paediatric Investigation Plan and Promising Innovative Medicine Designation for Leniolisib from UK MHRA

GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for ?6.9 million.

Pharming Group N.V. Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting

Pharming Group N.V. Announces Positive Results of Phase II/III Pivotal Clinical Study of Leniolisib for the Treatment of Activated PI3K Delta Syndrome

Pharming Receives Positive European Medicines Agency Decision on Paediatric Investigation Plan for Leniolisib in Europe

Pharming Announces Results from Clinical Trials for the Treatment of COVID-19 with RUCONEST®

Pharming Group N.V Announces Completion of Enrolment in Phase II/III Study with Leniolisib for Activated Pi3k Delta Syndrome

Pharming Group N.V. to Report Fiscal Year 2020 Final Results on Apr 06, 2021

Pharming Group N.V. to Report First Half, 2021 Results on Aug 05, 2021

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies